In a Phase II clinical trial using bicalutamide in patients with AR-positive and ER/PR-negative metastatic BC the most commonly reported adverse events were fatigue, hot flushes, limb oedema, and aspartate aminotransferase (AST) and alkaline aminotransferase (ALT) elevation (Gucalp et al., 2013). Here, PGR is linked to breast cancer.